CLEAR imaging maps many proteins with one dye

A JNCASR platform images an open-ended number of proteins using a single fluorophore, by erasing each round of signal with a pulse of ultraviolet light.

What happened

• Scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru — an autonomous institute of the Department of Science and Technology (DST) — reported a new fluorescence-imaging platform named CLEAR (Cleavable Light-Erased Antibody Reporter).
• The platform lets researchers visualise a very large number of distinct proteins inside the same tissue sample using just one fluorescent dye, instead of needing a separate colour for every target.
• The trick is a light-cleavable probe: after each image is captured, a gentle pulse of 365 nm LED light erases the fluorescent signal, freeing the same colour channel to label and image the next set of proteins.
• The team led by Prof. Sarit S. Agasti designed and synthesised the CLEAR probes; the method was demonstrated in immune-cell systems through collaboration with the Indian Institute of Science (IISc).
• The work was published in Chemical Science, a journal of the Royal Society of Chemistry.
• Listed applications span cancer biology, immunology, neurological disorders, spatial proteomics and precision medicine.

Background & context

A cell is not run by a single molecule but by hundreds of proteins acting together — which protein sits next to which, and in what neighbourhood of a tissue, is often the whole story of a disease. Reading that map is the job of protein imaging. The standard tool is immunofluorescence: an antibody is tagged to a fluorescent dye (a fluorophore), the antibody locks onto its target protein, and a microscope photographs where the dye glows. The limitation is colour. Each fluorophore emits in a narrow band of the light spectrum, and only a handful of these bands can be told apart at once before their colours overlap. In practice a single experiment can usually distinguish only about four to five proteins — a hard ceiling when a tumour or an immune response involves dozens.

The field's answer to that ceiling is high-plex (multiplexed) imaging — methods that build up a picture of many proteins by imaging them in successive rounds rather than all at once. Existing approaches typically either strip the antibodies off the sample chemically between rounds (which can damage delicate tissue) or cycle dyes on and off through slow, multi-step chemistry. CLEAR belongs to this multiplexed family but changes the erasing step: instead of harsh chemical stripping, it photochemically cleaves the dye from the probe with a brief flash of long-wave ultraviolet light. The signal simply switches off, the same colour channel is reused, and the cycle repeats. Because each round uses one fluorophore in one spectral window, the number of proteins that can be mapped is no longer capped by how many colours fit in the spectrum — it is capped only by how many labelling-and-erasing cycles the sample can endure.

It helps to understand why the choice of 365 nm light matters. That wavelength sits in the long-wave ultraviolet (UV-A) band — energetic enough to break the specific chemical bond ("cleave" the linker) that ties the dye to the antibody probe, yet gentle enough, delivered as a brief LED pulse, to spare the surrounding tissue and the antibodies still bound to it. The dye is not bleached at random; it is cleaved at a designed, light-sensitive point. That controlled removal is what makes the next labelling round clean, so the same fluorescence channel can be reused again and again without the colours from earlier rounds bleeding into later ones. The design problem the team solved is therefore largely a synthetic-chemistry one — building probes whose linker is stable during imaging but snaps predictably under a defined dose of UV light.

The platform sits inside a deliberate Indian research chain: the science is from a DST autonomous institute (JNCASR), the biological validation came from a peer national institution (IISc), and the result was placed in an international peer-reviewed journal (Chemical Science). This is the same DST stable that, on this very news day, was also visible elsewhere — the Centre and West Bengal moving to roll out central science and innovation schemes, and Dr Jitendra Singh marking the 150-year celebration of the Indian Association for the Cultivation of Science (IACS), the institute associated with C. V. Raman — underscoring that CLEAR is one node in a broader push on indigenous deep-science capability. JNCASR itself, set up in 1989 and named after India's first Prime Minister, is a deemed university and one of DST's flagship basic-research centres, working across chemistry, materials, biology and theoretical sciences.

For orientation, it is worth separating the two ideas the news fuses together. The "single-fluorophore" claim is about economy of colour — one dye standing in for what used to need many. The "erasable" claim is about reuse over time — switching that one dye off so the cycle can repeat. Older multiplexed methods achieved breadth by adding more colours or by physically removing antibodies between rounds; CLEAR achieves it by optically resetting a single colour. Holding those two ideas apart is exactly the kind of distinction a statement-based Prelims question tends to probe.

For Prelims

• Full form: CLEAR = Cleavable Light-Erased Antibody Reporter.
• What it is: a fluorescence-imaging platform / probe chemistry for high-plex (multiplexed) protein imaging — not a drug, not a microscope, not a scheme.
• Developed at: JNCASR, Bengaluru — an autonomous institute under the Department of Science and Technology (DST), Ministry of Science & Technology.
• Lead researcher: Prof. Sarit S. Agasti's group designed and synthesised the probes; IISc collaborated on immune-cell validation.
• Core mechanism: a light-cleavable probe — a 365 nm LED pulse (long-wave ultraviolet) cleaves the dye and erases the fluorescent signal, so the same spectral window is reused over many cycles.
• Key advantage: maps a large, open-ended number of proteins with a single fluorophore, breaking the usual ~4–5-colour limit of conventional immunofluorescence.
• Published in: Chemical Science (Royal Society of Chemistry).
• Applications: cancer biology, immunology, neurological disorders, spatial proteomics and precision medicine.
• Key terms to know: Fluorophore — a molecule that glows when illuminated. Immunofluorescence — using dye-tagged antibodies to locate proteins. Proteomics — the large-scale study of the full set of proteins (the "proteome"); spatial proteomics adds the dimension of where each protein sits within a tissue. Multiplexing / high-plex — reading many targets in one sample.
• What it is NOT: CLEAR is not a gene-editing tool, not a vaccine, and not a new microscope — it is a probe-and-erase labelling chemistry that runs on ordinary fluorescence microscopes. The novelty is the light-erasable dye, not new hardware. It also does not rely on chemical antibody-stripping; it erases optically with UV light.
• The parent set (for "match / how many" questions): CLEAR is one of a growing family of multiplexed imaging methods that image many proteins in cycles rather than simultaneously; conceptually it complements other ways of reading tissue molecule-by-molecule (single-cell and spatial '-omics' techniques). What distinguishes CLEAR within that set is its single-fluorophore, light-erased approach.
• Institutional anchor: JNCASR was established in 1989 at Bengaluru and functions as a DST autonomous research institute; remember the DST parentage, as the exam often tests which ministry/department a named institute sits under.

Why it matters

The problem CLEAR addresses is concrete and clinical. Diseases like cancer and many neurological and immune disorders are not driven by a single marker but by the spatial arrangement of many proteins — which immune cell is touching which tumour cell, and what each is expressing. The old four-to-five-colour ceiling forced researchers either to run many separate samples (losing the single tissue's true geometry) or to use slow, tissue-damaging stripping cycles. By letting a single dye be switched off optically and reused, CLEAR makes it feasible to read a far richer protein map from one precious clinical sample — for example, a single tumour biopsy — without exhausting it. For diagnostics this means more of the disease's "wiring diagram" recovered per sample; for research it advances spatial proteomics, a frontier that links molecular identity to physical location in tissue. There is also a cost and access angle: a method that relies on one inexpensive fluorophore and a standard 365 nm LED rather than a battery of specialised dyes and exotic optics is, in principle, cheaper to run and easier to deploy in ordinary laboratories — relevant for a country trying to widen the base of advanced biomedical research beyond a few elite centres. For the exam, the larger significance is that this is an indigenous, DST-funded basic-science platform with a credible path to precision-medicine application — a clean example of India producing original tools, not just adopting imported ones.

A word of caution on how to read such announcements: CLEAR is at the stage of a published, peer-reviewed laboratory method demonstrated in immune-cell systems, not an approved clinical diagnostic in hospitals. The release frames cancer and neurological-disease detection as applications the platform could facilitate, which is the honest claim — the bridge from a proven imaging chemistry to a routine clinical test still runs through validation, standardisation and regulatory steps. Stating that accurately is itself good exam discipline: distinguish a research capability from a deployed service.

For Mains